<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Defibrotide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Defibrotide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Defibrotide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107692" href="/d/html/107692.html" rel="external">see "Defibrotide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="109573" href="/d/html/109573.html" rel="external">see "Defibrotide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46387167"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Defitelio</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871442"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Defitelio</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14214047"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent;</li>
<li>
                        Thrombolytic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F14214094"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Utilize baseline body weight (prior to the preparative hematopoietic stem cell transplantation regimen) to calculate the defibrotide dose. Ensure that patients are hemodynamically stable (on no more than 1 vasopressor agent) and are not experiencing clinically significant bleeding prior to defibrotide administration. Do not initiate defibrotide in patients with active bleeding.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fda31e6-64b5-4d6d-b6a2-e16bffb4adc3">Hepatic sinusoidal obstruction syndrome, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic sinusoidal obstruction syndrome (formerly called veno-occlusive disease), treatment: </b>
<b>IV:</b> 6.25 mg/kg every 6 hours for at least 21 days and up to a maximum of 60 days (until sinusoidal obstruction syndrome resolution or hospital discharge) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26825712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26825712'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992061"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Defibrotide is not removed by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50989365"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dot drugH1Div" id="F46420414"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption>
<b>Defibrotide Treatment Modifications for Toxicity or Invasive Procedures</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Event</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Recommended Action</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Bleeding</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Persistent, severe, or potentially life-threatening</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold defibrotide. Treat the cause of bleeding and provide supportive care as clinically indicated. Consider resuming treatment (at the same dose and infusion volume) when bleeding has stopped and the patient is hemodynamically stable.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Recurrent significant bleeding</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue defibrotide permanently; do not resume. Provide supportive care.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypersensitivity reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe or life-threatening (anaphylaxis)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue defibrotide permanently; do not resume.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Invasive procedures</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">There is no known reversal agent for defibrotide profibrinolytic effects. Discontinue defibrotide infusion at least 2 hours prior to an invasive procedure. Resume defibrotide treatment after the procedure, as soon as any procedure-related risk of bleeding is resolved.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F14214095"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F14214093"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="109573" href="/d/html/109573.html" rel="external">see "Defibrotide: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Utilize baseline body weight (prior to the preparative hematopoietic stem cell transplantation regimen) to calculate the defibrotide dose. Ensure that patients are hemodynamically stable (on no more than one vasopressor agent) and are not experiencing clinically significant bleeding prior to defibrotide administration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fda31e6-64b5-4d6d-b6a2-e16bffb4adc3">Hepatic sinusoidal obstruction syndrome, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 6.25 mg/kg/dose every 6 hours for at least 21 days; if signs and symptoms of SOS have not resolved, continue until SOS resolution or up to a maximum of 60 days. Based on trial experience, may round doses to the nearest 5 mg for patients ≤35 kg, and to the nearest 10 mg for patients &gt;35 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767845'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing</b>
<b>adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Defibrotide Treatment Modifications for Toxicity or Invasive Procedures</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Event</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Recommended Action</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Bleeding</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Persistent, severe, or potentially life-threatening</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold defibrotide. Treat the cause of bleeding and provide supportive care as clinically indicated. Consider resuming treatment (at the same dose and infusion volume) when bleeding has stopped and the patient is hemodynamically stable.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Recurrent significant bleeding</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue defibrotide permanently; do not resume. Provide supportive care.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypersensitivity reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe or life-threatening (anaphylaxis)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue defibrotide permanently; do not resume.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Invasive procedures</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">There is no known reversal agent for defibrotide profibrinolytic effects. Discontinue defibrotide infusion at least 2 hours prior to an invasive procedure. Resume defibrotide treatment after the procedure, as soon as any procedure-related risk of bleeding is resolved.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F51090539"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Defibrotide is not removed by hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51090540"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F14214062"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (37%; severe hypotension: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (24%), nausea (16%), vomiting (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (59%; grade 4: ≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;2%; including anaphylaxis and angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Graft versus host disease (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (3%), sepsis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage (2%), intracranial hemorrhage (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (5%), pulmonary alveolar hemorrhage (9%), pulmonary hemorrhage (4%), pulmonary infiltrates (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Genitourinary: Hematuria (Nauffal 2022)</p></div>
<div class="block coi drugH1Div" id="F46420406"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to defibrotide or any component of the formulation; concomitant administration with systemic anticoagulant or fibrinolytic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F14214051"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Defibrotide may increase the risk of bleeding (based on increased activity of fibrinolytic enzymes in vitro).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (eg, rash, urticaria, and angioedema) have been reported (rare). One patient with a history of previous defibrotide exposure experienced an anaphylactic reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Porcine derived: Defibrotide is derived from porcine tissue.</p></div>
<div class="block foc drugH1Div" id="F46387168"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Defitelio: 200 mg/2.5 mL (2.5 mL)</p></div>
<div class="block geq drugH1Div" id="F14214046"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46817089"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Defitelio Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/2.5 mL (per mL): $532.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871443"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Defitelio: 200 mg/2.5 mL (2.5 mL)</p></div>
<div class="block adm drugH1Div" id="F14214096"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse over 2 hours using a 0.2 micron in-line filter. Flush the IV line (peripheral or central) with D5W or NS immediately before and after administration. Do not administer with other medications concurrently via the same infusion line.</p></div>
<div class="block admp drugH1Div" id="F52614147"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Infuse over 2 hours using a 0.2 micron in-line filter. Flush the IV line with D5W or NS immediately before and after administration. Do not administer with other medications.</p></div>
<div class="block use drugH1Div" id="F46229946"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hepatic sinusoidal obstruction syndrome, treatment: </b>Treatment of hepatic sinusoidal obstruction syndrome (formerly called veno-occlusive disease) in adult and pediatric patients with renal or pulmonary dysfunction following hematopoietic stem cell transplant.</p></div>
<div class="block mst drugH1Div" id="F14214042"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Defibrotide may be confused with dofetilide</p>
<p style="text-indent:-2em;margin-left:4em;">Defitelio may be confused with dofetilide</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46361050"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46361047"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Defibrotide may enhance the anticoagulant effect of Anticoagulants. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Defibrotide may enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of hemorrhage may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: May diminish the therapeutic effect of Thrombolytic Agents. Thrombolytic Agents may diminish the therapeutic effect of Tranexamic Acid.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F46420404"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F46420405"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if defibrotide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding during defibrotide treatment is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F14214098"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor closely for hypersensitivity reactions, particularly in patients who have received defibrotide previously; if hypersensitivity occurs, monitor until resolved. Monitor for signs and symptoms of hepatic sinusoidal obstructive syndrome; monitor closely for signs of bleeding.</p></div>
<div class="block pha drugH1Div" id="F14214071"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Defibrotide augments plasmin enzymatic activity to hydrolyze fibrin clots. It reduces endothelial cell (EC) activation and increases EC-mediated fibrinolysis by increasing tissue plasminogen activator and thrombomodulin expression, as well as by decreasing von Willebrand factor and plasminogen activator inhibitor-1 expression.</p></div>
<div class="block phk drugH1Div" id="F14214073"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8.1 to 9.1 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 93% to human plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Polynucleotides are metabolized via nucleases, nucleotidases, nucleosidases, deaminases, and phosphorylases to oligonucleotides, nucleotides, nucleosides, and then to the free 2’-deoxyribose sugar, purine and pyrimidine bases.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: &lt;2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (5% to 15% of total dose).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 3.4 to 6.1 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51220956"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Defibrotide AUC was 50% to 60% higher in patients with severe renal impairment or ESRD as compared to patients with normal renal function. C<sub>max</sub> was 35% to 37% higher (following single- and multiple-dose administration) in patients with severe renal impairment versus healthy subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059504"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Defitelio | Prociclide</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Defitelio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Defitelio.1">
<a name="Defitelio.1"></a>Defitelio (defibrotide) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; December 2022.</div>
</li>
<li>
<div class="reference">
                  Defitelio (defibrotide) [product monograph]. Montreal, Quebec, Canada; CGF Pharmatech; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14661036">
<a name="14661036"></a>Defitelio (defibrotide) [summary product characteristics]. Villa Guardia, Italy: Gentium SpA; March 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/14661036/pubmed" id="14661036" target="_blank">14661036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767845">
<a name="29767845"></a>Kernan NA, Grupp S, Smith AR, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Br J Haematol</i>. 2018;181(6):816-827. doi:10.1111/bjh.15267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/29767845/pubmed" id="29767845" target="_blank">29767845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34666352">
<a name="34666352"></a>Nauffal M, Kim HT, Richardson PG, et al. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. <i>Blood Adv</i>. 2022;6(1):181-188. doi:10.1182/bloodadvances.2021005410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/34666352/pubmed" id="34666352" target="_blank">34666352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26825712">
<a name="26825712"></a>Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i>. 2016;127(13):1656-1665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/defibrotide-drug-information/abstract-text/26825712/pubmed" id="26825712" target="_blank">26825712</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83451 Version 141.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
